Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Deep learning-based rapid generation of broadly reactive antibodies against SARS-CoV-2 and its Omicron variant.

ABSTRACT:

SUBMITTER: Lou H

PROVIDER: S-EPMC9514701 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Deep learning-based rapid generation of broadly reactive antibodies against SARS-CoV-2 and its Omicron variant.

Lou Hantao H Zheng Jianqing J Fang Xiaohang Leo XL Liang Zhu Z Zhang Meihan M Chen Yu Y Wang Chunmei C Cao Xuetao X

Cell research 20220927 1

PMID: 36167982

Similar Datasets

Profiling of human monoclonal antibodies targeting SARS-CoV-2 Omicron variant

Project description:We generated LNP-mRNA encoding B.1.1.529 SARS-CoV-2 spike, and intramuscularly administered it in a human IgG and IgK knock-in mouse. Single cell VDJ-seq unveiled the sequences of human monoclonal antibodies targeting the B.1.1.529 SARS-CoV-2 spike protein.

2022-07-01 | GSE203030 | GEO

Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses.

Project description: Not available

| S-EPMC8792449 | biostudies-literature

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

Project description: Not available

| S-EPMC9212999 | biostudies-literature

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.

Project description: Not available

| S-EPMC9531318 | biostudies-literature

Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants.

Project description: Not available

| S-EPMC11742922 | biostudies-literature

Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant.

Project description: Not available

| S-EPMC12925763 | biostudies-literature

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.

Project description: Not available

| S-EPMC9044386 | biostudies-literature

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.

Project description: Not available

| S-EPMC11445456 | biostudies-literature

Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants

Project description:For rapidly mutating viruses such as influenza viruses and SARS-CoV-2, immune memory recalled by antigenically drifted variants primarily comprises antibodies that cross-react to the priming strain rather than de novo elicited responses, a phenomenon termed original antigenic sin or immune imprinting. The composition and functionality of de novo responses elicited by variant exposures remain unclear. Here, we isolated and characterized hundreds of recall and de novo neutralizing monoclonal antibodies after sequential exposures to SARS-CoV-2 variants in ancestral-imprinted humans. De novo variant type-specific antibodies used different V(D)J genes that were closer to germline sequence, potently neutralized future variants, and targeted distinct receptor binding domain epitopes compared to ancestral cross-reactive (recall) antibodies. Nevertheless, neutralizing responses to the updated 2024-2025 booster were predominantly ancestral cross-reactive. These results reveal the distinct contributions of imprinted and de novo antibodies to a balanced immune response and underscore the benefit of updated booster vaccines which augment both subsets.

2026-07-06 | GSE325987 | GEO

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.

Project description: Not available

| S-EPMC10063446 | biostudies-literature